NOMINATIONS/RE-NOMINATIONS TO THE 2013 HESI BOARD OF TRUSTEES

Eleven trustees on the HESI Board completed their terms at the conclusion of the 2013 Annual Meeting, and one trustee resigned. Six of these trustees will be re-nominated for another three-year term and three will be re-nominated for two-year terms. They will be joined on the Board by three new trustees who will serve 3-year terms, bringing the HESI Board to its full complement of 31 trustees.

The HESI Nominating Committee identified the following roster of nominees/re-nominees, which include seven public and seven private (e.g., representing sponsor companies) positions:

**NOMINEES:**

Patrick D. Guiney, PhD, S.C. Johnson & Son, Inc. (3-year term)
Atsushi Sambuissho, PhD, Daiichi-Sankyo, Inc. (3-year term)
Martin van den Berg, PhD, Utrecht University (3-year term)

**RE-NOMINEES:**

Prof. Alan Boobis, Imperial College London (2-year term)
Dr. Samuel Cohen, University of Nebraska Medical Center (2-year term)
Dr. Dennis Devlin, Exxon Mobil Corporation (3-year term)
Dr. Peggy Guzzie-Peck, Johnson and Johnson (3-year term)
Dr. Martin Philbert, University of Michigan (3-year term)
Dr. Craig Rowlands, Dow Chemical (3-year term)
Dr. Lewis Smith, Medical Research Council (2-year term)
Dr. James Stevens, Eli Lilly & Co. (3-year term)
Dr. Jan Willem van der Laan, Medicines Evaluation Board (3-year term)
Boobis, Alan R., OBE, PhD
Dr. Alan Boobis is professor of biochemical pharmacology in the Department of Medicine, Imperial College London and Director of the Public Health England Toxicology Unit. He has been a member of Imperial College London (initially at the Royal Postgraduate Medical School, which merged with the College in 1997) for over 35 years. His main research interests lie in mechanistic toxicology, drug metabolism, toxicity pathway analysis and increasingly over the last 20 years or so, in the application of knowledge in these areas to risk assessment. He has published over 220 original research papers (H-factor ~60) and until recently was an Editor-in-Chief of Food and Chemical Toxicology. He is a member of a number of international advisory committees, including co-chair of the WHO Mode of Action Steering group, JECFA (veterinary residues - chair) and JMPR (alternating chair). He was a member (1993-9) and deputy chair (1999-2002) of the UK Advisory Committee on Pesticides. He was a member (2003-9) and deputy chair (2009-12) of the UK Committee on Toxicity, a member of the UK Committee on Carcinogenicity (2003-2012), the EFSA Panel on Contaminants in the Food Chain (2009-2012) and a member (2003-6) and deputy chair (2006-9) of the EFSA Panel on Plant Protection Products. He is a member and a past chair of the Board of Trustees of ILSI HESI and is vice president of ILSI Europe. He is also currently a member of the Board of Trustees of ILSI. He is involved in several HESI, ILSI RF and ILSI Europe projects. He is a fellow of the Society of Biology and of the British Toxicology Society. He has served as president of Eurotox and received the Merit Award in 2009. He is a past chair of the British Toxicology Society and received the John Barnes Prize Lectureship in 2013. He received an OBE in 2003 for his work on the risk assessment of pesticides.

Cohen, Samuel M., MD, PhD
Dr. Samuel M. Cohen received his MD and PhD degrees from the University of Wisconsin – Madison in 1972. He completed a residency in anatomic and clinical pathology at St. Vincent Hospital, Worcester, Massachusetts, in 1975, and became board certified in pathology the following year. He was a visiting professor in the department of Dr. Nobuyuki Ito at Nagoya City University Medical School, Nagoya, Japan, from 1976 to 1977, a staff pathologist at St. Vincent Hospital from 1975 to 1981, and associate professor of pathology at the University of Massachusetts Medical School from 1977 to 1981. In 1981, he became Professor and Vice Chairman of Pathology in the College of Medicine and Professor at the Eppley Institute, University of Nebraska Medical Center. In 1992, he was named Chairman of the Department of Pathology and Microbiology at Nebraska, continuing in that position until 2007. Dr. Cohen’s research has focused on mechanisms of carcinogenesis, with a focus on the role of cell proliferation in the carcinogenic process, primarily utilizing the urinary bladder as a model system. Most recently this has involved investigations into the mechanisms of bladder carcinogenesis produced by arsenicals and PPAR agonists. Research with PPAR agonists has led to investigations into mechanisms of induction of hemangiosarcomas. In addition, his research has involved clinical investigations of various aspects of urologic pathology and extrapolation between animals and humans. He also has been active in mathematical modeling efforts and applications to risk assessment. This research has resulted in more than 300 publications. He has been a member of numerous NIH, EPA, FDA, WHO, IARC and National Academy of Sciences study sections and scientific panels, was a member of the National Toxicology Program’s Board of Scientific Counselors, and is currently on the Board of Scientific Counselors of the National Institute of Environmental Health Sciences (NIEHS). He is on the editorial boards of several scientific journals in the areas of toxicology, pathology, and carcinogenesis, and is a reviewer for several other journals. He was president of the SOT Carcinogenesis Specialty Section and the SOT Central States Chapter of the Society of Toxicology. He was the recipient of the Society’s Arnold J. Lehman Award in 2001, was named Distinguished Scientist in Cancer Research by the Japanese Foundation for Cancer Research in 2004, and received the George H. Scott Award from the Toxicology Forum and the Lifetime Achievement Award from the Association for Environmental Health and Science in 2012. He continues to be active in human surgical pathology, subspecializing in urologic pathology, and is listed as one of the “Best Doctors in America.” He has been actively involved with ILSI, RSI, and HESI since 1985, serving as a member of the HESI Board of Trustees since 2001 (Vice Chairman, 2004-6; Chairman, 2006-8) and the ILSI Board since 2007 (Chairman, 2012-2014).

Devlin, Dennis J., PhD
Dr. Dennis Devlin joined Exxon Biomedical Sciences in 1987. His early work focused on site remediations and product risk assessments. He transferred to the Brussels headquarters of Exxon Chemical International, Inc. in 1991 where he directed the toxicology program for European Exxon business groups and area offices. Following the merger of Exxon and Mobil, he became Director of Toxicology and Environmental Sciences, providing global affiliates and support organizations with consulting services, science development, and field support. In 2009, he assumed the role of Senior Environmental Health Advisor for Exxon Mobil Corporation where he provides strategic guidance for environmental health policy and planning. Dennis is a Board Trustee of the International Life Sciences Institute (ILSI), President of the ILSI Health and Environmental Sciences Institute, Chairman of the Petroleum Industry High Production Volume Testing Committee, Chairman of the American Petroleum Institute’s Exploration and Production Health Issues Group, and a member of the Institute of Medicine of
the National Academies Roundtable on Environmental Health Sciences, Research, and Medicine. Dennis received his B.A. in Biology from St. Louis University, M.S. in Environmental Engineering from Washington State University and a Ph.D. in Toxicology from Dartmouth College.

**Guiney, Patrick D., PhD**

Pat Guiney is Director of Global Environmental Safety at S.C. Johnson & Son, Inc. He is responsible for conceiving and implementing global environmental toxicology research strategies and policies. Pat has 36 years of broad-based experience in human health and ecological risk assessments. He has served internationally as chair of several multidisciplinary scientific committees and advisory panels including the EPA's Endocrine Disrupter Screening and Testing Standardization and Validation Ecotoxicology Advisory Panel. He is currently serving as the President of the Society of Environmental Toxicology and Chemistry (SETAC)- North America and on the SETAC World Council. He is a co-developer of S.C. Johnson's award-winning Greenlist Program (an integrated computer-based approach for designing superior performing, environmentally responsible products from concept to market). He is also co-recipient of EPA's 2006 Green Chemistry Award for work on Greenlist and co-recipient of the 2006 Presidential Award for Corporate Leadership-Environmental Sustainability (The Ron Brown Award). Dr. Guiney received his Ph.D. in Environmental Toxicology from the University of Wisconsin-Milwaukee. He has conducted research into the transport, bioaccumulation and fate of toxic substances at various levels of biological organization (molecular/biochemical to field studies). His current research interest include the application of molecular based models for screening and prioritizing potential endocrine disrupters, quantitative structure-activity relationships for investigating mechanisms of toxicity, ecological exposure assessment modeling for risk assessment, and alternative methods for predicting the bioaccumulation of persistent chemicals. He holds adjunct faculty appointments at the University of Wisconsin-Madison and Milwaukee, and has published over 45 peer-reviewed scientific papers in these areas of research.

**Guzzie-Peck, Peggy J., PhD**

Dr. Peggy J Guzzie-Peck holds M.S. and Ph.D. degrees from the University of Pittsburgh in Toxicology/Human Genetics with an emphasis on Genetic Toxicology. She has broad experience in various aspects of toxicology and has been a diplomate of the American Board of Toxicology since 1987. Peggy joined Johnson & Johnson in the Global Preclinical Development organization in 2007 and is currently the Vice President and Global Head of Toxicology/Pathology and Laboratory Animal Medicine, with responsibilities for developing the strategy and delivering the operational goals at sites both in Raritan, NJ and Beersel, Belgium. Before joining Johnson & Johnson PCD, she has held several management-level positions at Pfizer, Inc. where she headed Genetic Toxicology in Groton, CT for over 10 years and led other disciplines including Safety Pharmacology, General Toxicology and Comparative Medicine as an Executive Director of Toxicology in Amboise, France. Prior to her career at Pfizer, she managed the Genetic Toxicology group at G.D. Searle and coordinated the outsourcing of worker safety and environmental impact testing. Throughout her career, she has served on several international expert work groups in Preclinical Safety, Genetic Toxicology, In Vitro Toxicology, Phototoxicity and Safety Pharmacology. She was a member of the PhRMA Preclinical Safety Leadership Committee, chaired the PhRMA Genetic Toxicology and Phototoxicity Technical Groups, served on the council for the Environmental Mutagen Society, and chaired the Genetic Toxicology Association. She has also taught courses and lectured at several universities on various topics including Preclinical Safety Testing, Structural Activity Relationships, Carcinogenicity, Toxicoinformatics, and Genetic Toxicology.

**Philbert, Martin A., PhD**

Dr. Martin Philbert became dean of the University of Michigan School of Public Health on January 1, 2011, having previously served as senior associate dean for research at the school since 2004. He arrived at UM in 1995 from Rutgers’ Neurotoxicology Laboratories, where he was a research assistant professor. He has maintained a continuously federally funded portfolio of basic research activities throughout his career. Most recently his work has been funded by the National Institutes of Health, the Department of Air Force and the National Cancer Institute. At the national level, he is recognized for his expertise in neurotoxicology and experimental neuropathology. Dr. Philbert earned his Ph.D in Neurochemistry/Experimental Neuropathology in 1987 from London University (England). He is the author of numerous research publications in top peer-reviewed journals, and one book. In 2012, Dr. Philbert was elected to membership in the Institute of Medicine of the National Academy of Sciences.

**Rowlands, J. Craig, PhD, DABT**

Dr. Craig Rowlands is a Senior Scientist at The Dow Chemical Company’s Toxicology and Environmental Research and Consulting Organization (TERC). Dr. Rowlands is also the Group Leader of Advanced Materials Product Sustainability Consulting and leads TERC’s Chemicals & Health Science Policy Group. He directs a research program on environmental pollutants and applied research in chemical risk assessment. Dr. Rowlands is an adjunct professor at Michigan State University, Center for Integrative Toxicology and holds leadership positions in the Society for Toxicology, the American Chemistry Council and the International Life Sciences Institute, Health and Environmental Science Institute. Dr. Rowlands completed his Ph.D. in Toxicology at Texas A&M University and performed postdoctoral research in molecular endocrinology at the Karolinska Institute in Stockholm, Sweden. Prior to coming to Dow, Dr. Rowlands worked at the US FDA. Dr. Rowlands is a Diplomate of the American Board of Toxicology (DABT) and a Fellow of the American College of Nutrition (FACN).
Sambuissho, Atsushi, PhD  
Dr. Atsushi Sambuissho is currently Science Advisor at the Medicinal Safety Research Laboratory (R&D Division) of Daiichi-Sankyo Co., Ltd. He joined Sankyo Co. Ltd. in 1992, and has held several positions within the company both before and after Sankyo merged with Daiichi to become Daiichi-Sankyo in 2007. Dr. Sambuissho earned his PhD in 1988 from the College of Veterinary Medicine at the Ohio State University (Columbus, OH). He is a diplomate of the Japanese Society of Toxicology and the Japanese Teratology Society.

Smith, Lewis, PhD, FRCP, FBTS  
Professor Lewis Smith is currently working at the University of Leicester. He is professor of Biochemical Toxicology and contributes to various research initiatives. He was the initiating Director for three years of the Centre for Translational Therapeutics which is now led by Professor Andrew Tobin. Professor Smith began his career in 1971 at ICI Central Toxicology Laboratories and during which time completed his PhD studies under the supervision of Professor Norman Aldridge at the MRC Toxicology Unit in Carshalton. He left ICI in 1991 to become Director of the MRC Toxicology Unit which he relocated two years later from Carshalton to its current location within the University of Leicester. Professor Smith has published extensively on the mechanisms of toxicity of chemicals, pesticides and drugs and is particularly interested in the extrapolation of experimental data to man. In 1998 he moved as Director to Zeneca Central Toxicology Laboratory and assumed responsibility for Health and Environmental Safety. In 2002 he transferred to Syngenta Basel as Head of Development and then to other appointments in Research and Development. On retiring from Syngenta he returned to the University of Leicester. Professor Smith is a past President of the British Toxicology Society as well as having held different position on the Society’s committees. He is a past President of HESI and is currently a Trustee (Board member) of both HESI and ILSI. Professor Smith is also a Board member of IUTOX and is Chairman of the Toxicologists Recognition Task Force which is attempting to professionalize the qualifications and certification of Toxicologists on a global basis.

Stevens, James L., PhD  
Dr. Stevens received his PhD in Pharmacology from the University of Minnesota in 1980 and was awarded a PRAT Fellowship from the National Institute of General Medical Sciences. He has held a number of positions including Senior Staff Fellow in the Bureau of Biologies, FDA (1983-1986), Senior Scientist (1986-1992) and then Executive Director (1992-1998) at the W. Alton Jones Cell Science Center, Lake Placid, NY, and Professor of Pathology at the University of Vermont (1998-2000). Dr. Stevens also served as a member of the Board of Directors for Upstate Biotechnology. He joined Lilly Research Laboratory in 2000 where he is a Distinguished Research Fellow. He was appointed a HESI Trustee in 2008 and to the NIGMS Science Advisory Council in 2009. He received the Achievement Award from the Society of Toxicology in 1994 and was elected a Fellow of the American Association for the Advancement of Sciences in 1996. His research interests focus on predictive and molecular/investigative toxicology and adverse drug reactions. He has published over 90 peer reviewed articles.

van den Berg, Martin, PhD  
Dr. Martin van der Berg started his activities within the Research Institute Toxicology of the University of Utrecht as an Associate Professor in Environmental Toxicology. In 1999 he was appointed Professor Veterinary Environmental Sciences and Environmental Toxicology at the Research Institute Toxicology, Faculty of Veterinary Medicine of the Utrecht University. In 2007 his professorship was upgraded to a chair in Toxicology at the Faculty of Veterinary Medicine. Currently he holds the position of Deputy Director and Head, Toxicology and Veterinary Pharmacology Division of the Institute for Risk Assessment Sciences, University of Utrecht, NL. IRAS has 150-175 scientific and technical staff members annually and three divisions; Toxicology & Pharmacology, Environmental Epidemiology and Veterinary Public Health. His main roles and responsibilities include (1) the development of research programs in toxicology at IRAS with special emphasis for the effect of environmental and food contaminants. Special attention is given to the development of toxicokinetic modelling, development of in vitro models and metabolic or steroidogenic processes of both xenobiotics as well as natural hormone like compounds; (2) integration of the fields of environmental and biochemical toxicology with special emphasis on the use of biochemical and molecular techniques with special emphasis on the chemoprevention of hormone dependent tumors; (3) coordination and participation in national and international organizations and advisory boards for risk assessment; (4) presentation and publication of scientific results in international journals, conference symposia and workshops; (5) training and courses in Toxicology for under and postgraduate students at the University of Utrecht; and (6) thesis supervisor (promotor).

van der Laan, Jan Willem, PhD  
Dr. Jan Willem van der Laan is senior assessor in Pharmacology and Toxicology for the Medicines Evaluation Board, located in Utrecht, the Netherlands. He is chair of the EMA/CHMP Safety Working Party. Dr. Van der Laan was since 1990 in the Section Pharmacology and Toxicology Assessment at the National Institute for Public Health and the Environment (RIVM, Bilthoven). In this function he was responsible for the advice on non-clinical safety aspects for the Netherlands ‘College’, the Medicines Evaluation Board. He moved with this group in 2012 to the Medicines Evaluation Board located in Utrecht. His contributions to the International Conference on Harmonization started in 1992 on Carcinogenicity Testing. Later he was EU rapporteur for S8 Immunotoxicity and for ICH S6 (R1) Addendum for the Preclinical testing of Biotechnology-derived Proteins. Now again, he is a member of the new Expert Working Group on Carcinogenicity testing, started in 2011.
ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE (HESI)
PROPOSED 2013 HESI BOARD OF TRUSTEES

Dr. Cynthia A. Afshari
Amgen, Inc.

Prof. Herman Autrup
University of Aarhus

Dr. Scott E. Belanger
The Procter & Gamble Company

Dr. Brian R. Berridge
GlaxoSmithKline

Prof. Alan R. Boobis
Imperial College London

Dr. Samuel M. Cohen
University of Nebraska Medical Center

Dr. Dennis J. Devlin
Exxon Mobil Corporation

Dr. Shoji Fukushima
Japan Bio assay Research Center

Dr. Jay I. Goodman
Michigan State University

Dr. Patrick D. Guiney
S.C. Johnson & Son, Inc.

Dr. Peggy J. Guzzie-Peck
Johnson & Johnson

Dr. Laurie A. Hanson
Pfizer Inc.

Dr. Ernie Harpur
Newcastle University

Prof. Serrine Lau
University of Arizona

Dr. Lois Lehman-McKeeman
Bristol-Myers Squibb Company

Dr. Charlene A. McQueen
Research Triangle Park, NC

Prof. Angelo Moretto
University of Milan

Dr. Timothy P. Pastoor
Syngenta Crop Protection, Inc.

Dr. Martin A. Philbert
University of Michigan

Dr. Robert W. Rickard
DuPont

Dr. J. Craig Rowlands
The Dow Chemical Company

Dr. Atsushi Sambui s s ho
Daichi Sankyo Co., Ltd.

Dr. Jiro Seki
Astellas Pharma Inc.

Dr. Lewis L. Smith
Medical Research Council

Dr. James L. Stevens
Eli Lilly and Company

Dr. Hiroyuki Tsuda
Nagoya City University

Dr. Martin van den Berg
Utrecht University

Dr. Jan Willem van der Laan
Medicines Evaluation Board

Dr. Bennard van Ravenzwaay
BASF SE

Dr. Kendall B. Wallace
University of Minnesota

Dr. Douglas C. Wolf
Research Triangle Park, NC
PROPOSED 2013 HESI EXECUTIVE COMMITTEE AND OFFICERS*
* TO BE APPROVED BY HESI BOARD ON JUNE 13, 2013

President (Term expires at close of 2015 Annual Meeting) Dr. Laurie Hanson (private)
Vice President (Term expires at close of 2015 Annual Meeting) Dr. Timothy Pastoor (private)
Chair (Term expires at close of 2014 Annual Meeting) Dr. Kendall Wallace (public)
Vice Chair (Term expires at close of 2014 Annual Meeting) Prof. Herman Autrup (public)
Secretary (Term expires at close of 2014 Annual Meeting) Dr. Charlene McQueen (public)
Treasurer (Term expires at close of 2014 Annual Meeting) Dr. Serrine Lau (public)
Past President (Term expires at close of 2014 Ann. Mtg.) Dr Dennis Devlin (private)
Member-at-Large (Term expires at close of 2014 Ann. Mtg.) Dr. Brian Berridge (private)
Member-at-Large (Term expires at close of 2014 Ann. Mtg.) Dr. Peggy Guzzie-Peck (private)
Member-at-Large (Term expires at close of 2014 Ann. Mtg.) Dr. Ernie Harpur (public)

2013 HESI REPRESENTATIVES TO THE ILSI BOARD OF TRUSTEES

Representative (Term expires at close of 2015 Annual Meeting) Dr. Alan Boobis (public)**
Representative (Term expires at close of 2014 Annual Meeting) Dr. Jay Goodman (public)
Representative (Term expires at close of 2016 Annual Meeting) Dr. Scott Belanger (private) **
Representative (Term expires at close of 2016 Annual Meeting) Dr. Samuel Cohen (public)**
Representative (Term expires at close of 2016 Annual Meeting) Dr. Dennis Devlin (private)**
Representative (Term expires at close of 2015 Annual Meeting) Dr. Lewis Smith (public)**

**ELECTED/RE-ELECTED BY ILSI AOM ON JANUARY 20, 2013
NOMINATIONS TO THE
2013-2014 HESI EMERGING ISSUES COMMITTEE

Seven positions on the HESI Emerging Issues Committee (EIC) become vacant at the conclusion of the 2013 Annual Meeting. Nominations were solicited for the following positions: a private sector Vice Chair (from among existing EIC Science Advisors), three private sector Science Advisors, and three public sector Science Advisors. At its February 2013 meeting, and in its capacity as nominating committee, the EIC prioritized the list of candidates, and recommends the following slate of nominees:

Vice Chair:
Dr. Ruth A. Roberts, AstraZeneca Safety Assessment UK (three-year term)

Private Sector Science Advisors:
Dr. Ann M. Blacker, Bayer CropScience (three-year term)
Dr. Michael J. Graziano, Bristol-Myers Squibb (three-year term)
Dr. Kathleen A. Shelton, DuPont Haskell Global Centers for Health and Environmental Sciences (three-year term)

Public Sector Science Advisors:
Dr. James E. Klaunig, Indiana University School of Medicine (re-nomination, three-year term)
Dr. Derek C.G. Muir, Environment Canada (re-nomination, three-year term)
Dr. Flavio A.D. Zambrone, University of Taubaté / Planitox (three-year term)
Ruth A. Roberts, PhD, FBTS, ATS, ERT, FRCPPath

Dr. Ruth Roberts is Senior Director of Toxicology at AstraZeneca and visiting Professor at the University of Birmingham, UK. She gained her PhD in Medical Oncology in 1987 before conducting post-doctoral research with the Imperial Cancer Research Fund in London. From 1990 to 2002, she led a research team at Zeneca (now Syngenta) Central Toxicology Laboratory focused on PPARα, apoptosis and the molecular basis of species differences in the response to drugs and chemicals. Her contribution to the fields of cancer biology, carcinogenesis and toxicology was recognised in 2002 when she received the Society of Toxicology (SOT) Achievement Award. In 2002, Ruth moved to France to become Director of Toxicology and Head of Early Safety for Aventis Pharma in Paris where she oversaw many regulatory and investigative toxicology projects. In 2004, Ruth took up a position as Director of Toxicology for AstraZeneca at Alderley Park, UK where she is responsible for pre-clinical toxicology input across the drug discovery and development portfolio. She is a member of the UK Department of Health Committee on Carcinogenesis (COC), past-president of the Carcinogenesis Specialty Section of SOT, and is a member of the executive committees of both the British Toxicology Society and EUROTX where she also sits on the scientific subcommittee. She has authored over 100 peer-reviewed papers, given over 40 invited lectures/presentations at international conferences, organized many symposia, and edited a book entitled *Apoptosis in Toxicology.*
Ann M. Blacker, PhD, DABT  
Dr. Blacker is Director, Regulatory Toxicology, for Bayer CropScience (BCS). She manages a team of regulatory toxicologists who provide expert support in toxicology to US business operations (CropScience, BioScience, and Environmental Science). The team advises BCS regulatory affairs, product safety management, and business groups of all developments and requirements with respect to toxicity studies and risk assessments, and provides expert support on strategic decisions. The Regulatory Toxicology team oversees the conduct of a variety of regulatory toxicity studies (e.g., acute, subacute, subchronic, chronic, genotoxicity, developmental toxicology, reproduction, carcinogenicity, and neurotoxicity (acute, subchronic, and developmental)), in addition to designing mechanistic studies to improve understanding of specific findings from regulatory studies. These studies are conducted in compliance with TSCA, FIFRA, OECD, and MAFF regulations under GLP guidelines.

Michael J. Graziano, PhD, DABT  
Dr. Graziano is Vice-President of Drug Safety Evaluation and is currently responsible for all GLP nonclinical safety testing at Bristol-Myers Squibb including sites in Mount Vernon, IN, and New Brunswick, NJ. Dr. Graziano has more than 25 years' experience as a toxicologist in the pharmaceutical industry. He joined Bristol-Myers Squibb as Executive Director in 2003 and was promoted to Vice President in 2006. Prior to joining BMS, he was Director of Anticancer and Antibacterial Toxicology Programs at Pfizer Pharmaceutical Research, Ann Arbor, MI (2000-2003) and was employed with Parke-Davis Pharmaceutical Research Division/Warner-Lambert Company from 1987-2000. He is author/co-author of numerous scientific publications and abstracts, many dealing with the preclinical safety of new anticancer agents. Dr. Graziano is the BMS preclinical representative on the PhRMA Clinical and Preclinical Development Committee, the HESI EFPIA Preclinical Safety Development Committee, and the Preclinical Safety Leadership Group in the IQ Consortium. He received a B.S. in Animal Science from Rutgers University, a M.S. in Veterinary Toxicology from Louisiana State University, a Ph.D. in Toxicology from the University of Kentucky, and was a Post-Graduate Research Toxicologist in Pesticide Chemistry and Toxicology at the University of California-Berkeley.

Kathleen A. Shelton, PhD  
Dr. Kathleen Shelton is Director, DuPont Haskell Global Centers for Health and Environmental Sciences. She is responsible for leading the organization and assuring Haskell's engagement in health and environmental science issues across DuPont. Haskell provides toxicological services to all businesses and functions across DuPont. Dr. Shelton is also Director, Central Research and Development, Enabling Technologies, and is responsible for leading the organizations that provide analytical, computational, and pilot scale services across DuPont. Dr. Shelton has worked at DuPont in various capacities since 1993. Recently, she was detailed to Geneva, Switzerland, where she led European advocacy efforts related to REACH implementation and chemicals management, including participation in the Product Stewardship Programme Council of the European Chemical Industry Association (CEFIC) and the Strategic Approach to International Chemicals Management (SAICM, part of the United Nations Environmental Programs). Dr. Shelton has a BS in Biology from the University of Notre Dame, and a PhD in Microbiology and Immunology from Hahnemann University (now part of Drexel University).
James E. Klaunig, PhD, ATS

Dr. James E. Klaunig is Professor and Director of Toxicology in the Department of Pharmacology and Toxicology at Indiana University School of Medicine. After receiving his BS in biology from Ursinus College, Collegeville, Pa, he received his PhD in experimental pathology (B. Trump, Mentor) from the University of Maryland, Baltimore, MD. After postdoctoral studies, he became assistant professor and then associate professor in the department of Pathology and Pharmacology at the Medical College of Ohio, Toledo, OH. Following a sabbatical year at the Chemical Industry Institute of Toxicology (J. Popp, Mentor) he took the professorship at Indiana University in 1991. His research has focused on the mechanisms of chemically induced carcinogenesis with emphasis on the epigenetic modes of action. His work has concentrated on studies involving multistage liver carcinogenesis with emphasis on the role of oxidative stress/oxidative damage, Kupffer cell activation, modulation of gap junctions, and cell growth/apoptosis in this process. He is active in the Society of Toxicology having served on elected and appointed committees over the past 16 years, including election as SOT Treasurer and Council member, President of the Carcinogenesis Specialty Section, President of the Ohio Valley SOT Regional Chapter, and member and Chair of the Education Committee. He has served as a member of the USEPA Science Advisory Board, a member of the National Toxicology Program Board of Scientific Advisors, and a member of the Board of Trustees of the ILSI Health and Environmental Sciences Institute (HESI). In 2002 he received the Kenneth P. DuBois Award from the Midwest Society of Toxicology Chapter. From Indiana University, he has also received the Otis R. Bowen, M.D., Distinguished Leadership Award and the Indiana University Board of Trustees’ Teaching Award. He is a Fellow in the Academy of Toxicological Sciences. He serves as a member of the Governor’s Council on Impaired and Dangerous Driving, the Indiana Pesticide Review Board and the Controlled Substances Board for the State of Indiana. He served as Chair of the Peroxisome Proliferation workgroup of the ILSI RSI Panel on the Human Relevance of Animal Tumors, Chair of the USEPA Scientific Advisory Board Human Health Research Strategy review panel, and as Chair of the review of the Environmental Carcinogenesis Division of the USEPA. After 13 years of service, he stepped down as the state toxicologist and Director of the State Department of Toxicology for the State of Indiana. His exemplary service to the State was recognized by the presentation by the Governor of Indiana with the Sagamore of the Wabash (the highest honor the State of Indiana can bestow for service to the State). He has published over 170 peer reviewed manuscripts and book chapters and has mentored many MS, Ph.D., and Postdoctoral Fellows in toxicology and chemical carcinogenesis. He is an Associate Editor of Toxicological Sciences and is on the Editorial Board of Toxicologic Pathology.

Derek C.G. Muir, PhD

Dr. Derek Muir is Senior Research Scientist and Section Head, Priority Contaminants, Fate and Bioaccumulation. He is also Adjunct Professor, Project Chief, and Research Scientist, Aquatic Ecosystems Protection Research Division, Water Science & Technology Directorate, Environment Canada. Dr. Muir’s research interests focus broadly on the environmental chemistry and biogeochemistry of persistent organic contaminants, mercury and other metals. A major focus is the development or refinement of analytical methodologies for newly emerging persistent chemicals such as fluorinated surfactants and brominated flame retardants. This involves use of liquid chromatography-tandem mass spectrometry and high resolution mass spectrometry. His major interests center on understanding bioaccumulation and bioavailability of persistent and bioaccumulative chemicals in the aquatic and terrestrial environments under field and laboratory conditions with special emphasis on food chain transfer. Field sites are in the Arctic and sub-arctic regions of Canada as well as in the Great Lakes. He has also worked on projects in Africa and the southeastern USA and collaborates extensively with scientists in the USA (Alaska), Denmark (Greenland), Norway, Sweden and the UK. Much of this work is done by graduate students and postdoctoral fellows, located at Canada Centre for Inland Waters (Burlington, ON) in collaboration with university colleagues. They are supported by technical personnel within the PSEx section in Burlington. He currently co-supervises four graduate students in Environmental Biology at the University of Guelph and serves on the advisory committees of three PhD students in Chemistry at the University of Toronto, as well as students at the University of Waterloo (Biology), University of Northern British Columbia, and Université Laval (Biologie).
Dr. Flavio Zambrone is a physician at the University of Taubaté, with residence training in Nephrology. He has an MD degree in Medicine from the University of Campinas (UNICAMP) where he is a Specialist in Public Health. He has served as a Specialist in Toxicology and Clinical Pharmacology at the University of Paris VII - Hospital Fernand Widal (France) and Professor of Toxicology at the Medical Sciences Faculty / University of Campinas (1983 – 2007). He is also Director of the Scientific Board of ILSI Brasil and is a member of the ILSI Board of Trustees as an academic scientist representative. He is a member of the American Academy of Clinical Toxicology. Dr. Zambrone is also Executive Director of Planitox, a consulting company in Toxicology, and President of the Brazilian Institute of Toxicology. He has experience in consultancy in Toxicology, Human Health Risk and Crisis Management, and development of new products, registration, reevaluation and stewardship related to safety of chemicals. He is responsible for the advocacy process of chemical substances, including defense strategies and participation in judicial lawsuits, and is a toxicology consultant in Environmental, Occupational, Experimental and Clinical Toxicology.
HESI EMERGING ISSUES COMMITTEE

PROPOSED ROSTER
(June 2013 – June 2014)

LEADERSHIP (one-year term in each leadership position)

Chair: Hal Zenick, PhD, US Environmental Protection Agency (term expires June 2015)
Vice Chair: Ruth A. Roberts, PhD, FBTS, ATS, ERT, FRCPath, AstraZeneca R&D (term expires June 2016)
Past Chair: Stephen J. Newsholme, BSc, BVetMed, MMedVet (Path), Diplomate ACVP, MRCVS, GlaxoSmithKline (term expires June 2014)

SCIENCE ADVISORS (public sector) (three-year terms)

Darlene Dixon, DVM, PhD, DACVP, National Institute of Environmental Health Sciences (term expires June 2014)
Jesse L. Goodman, MD, MPH, US Food and Drug Administration (term expires June 2014)
George Gray, PhD, George Washington University (term expires June 2014)
Toshihisa Ishikawa, PhD, RIKEN Yokohama Institute (term expires June 2015)
James E. Klaunig, PhD, ATS, Indiana University (renewed; term expires June 2016)
José E. Manautou, PhD, ATS, University of Connecticut (term expires June 2015)
Derek C.G. Muir, PhD, Environment Canada (renewed; term expires June 2016)
Russell S. Thomas, PhD, The Hamner Institutes for Health Sciences (term expires June 2015)
Flavio A.D. Zambrone, MD, PhD, University of Taubaté / Planitox (term expires June 2016)

SCIENCE ADVISORS (private sector) (three-year terms)

Cynthia A. Afshari, PhD, DABT, Amgen Inc. (term expires June 2014)
Robert A. Barter, PhD, ExxonMobil Biomedical Sciences (term expires June 2015)
Ann M. Blacker, PhD, DABT, Bayer CropScience (term expires June 2016)
Daniel A. Goldstein, MD, Monsanto Company (term expires June 2015)
Michael Graziano, PhD, DABT, Bristol-Myers Squibb (term expires June 2016)
Patrick D. Guiney, PhD, SC Johnson & Son, Inc. (term expires June 2014)
Kathleen A. Shelton, PhD, DuPont Haskell Global Centers for Health and Environmental Sciences (term expires June 2016)